ULTOMIRIS® Infusion Therapy
FlexCare administers ULTORMIRIS® infusion therapy (ravulizumab-cwvz) in comfortable infusion suites to treat patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, and generalized myasthenia gravis.
About ULTOMIRIS® Infusion Therapy
ULTOMIRIS infusion therapy is a biologic medication that is FDA-approved to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), hemolytic-uremic syndrome (aHUS), and generalized myasthenia gravis (gMG).
UTLOMIRIS infusion therapy is designed to bind to and block C5 proteins in the bloodstream. These proteins play an important role in triggering the immune system’s defense process. When working properly, C5 proteins help the body remove harmful pathogens. But if they are inappropriately triggered, they can cause damage to the body.
Conditions Treated by ULTORMIRIS® Infusion Therapy
Paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, and generalized myasthenia gravis are all rare diseases caused by complement system dysregulation. Typically, complement activation is a necessary function of the immune system, but when triggered incorrectly, it can cause the symptoms of aHUS, PNH, and gMG.
ULTOMIRIS infusion therapy is a treatment option for all three of these diseases. ULTOMRIS differs from other C5- inhibitors because it lasts longer in the bloodstream. Patients receiving ULTOMIRIS infusion therapy for PNH, aHUS, and gMG require less frequent infusions.
The out-of-pocket ULTOMIRIS cost will vary depending on your insurance coverage. If you have questions about your coverage, contact your insurance provider.
Many patients with commercial insurance qualify for the Alexion OneSource Copay Program which can help cover the ULTOMIRIS cost. For more information on ULTOMIRIS cost and financial resources, you may visit https://ultomirisgmg.com/cost-and-savings.
No patient should go without necessary treatment due to financial limitations. If you have questions about financial assistance opportunities, contact a member of our FlexCare team.
What to Expect During ULTOMIRIS® Infusion Therapy
The FlexCare team will administer your first two doses of ULTOMIRIS infusion therapy 2 weeks apart, and then every 8 weeks thereafter for adult patients. Each infusion will last around 1 hour in one of our comfortable infusion suites.
Leading up to your infusion, it’s important to take extra care of your health. Biologic medications target the immune system, which may increase the risk of infection during and after treatment. Check out our list of infusion therapy health tips that can help you stay healthy during ULTOMIRIS infusion therapy.
Most ULTOMIRIS side effects are mild to moderate if they occur. Upper respiratory infections and headaches are the most common, but other side effects can include diarrhea, nausea, vomiting, high blood pressure, and fever.
Download FlexCare’s ULTOMIRIS Patient Guide for more information on ULTOMIRIS infusion therapy at FlexCare Infusion Centers.
Getting Started With Infusion Therapy
If you have been prescribed ULTOMIRIS infusion therapy to treat PNH, aHUS, or gMG and would like to receive treatment at FlexCare, your doctor can easily send us a referral. If you have any questions, you can also contact FlexCare directly. We look forward to helping you soon.
If you have any questions about ULTOMIRIS or infusion therapy, contact us directly. We look forward to helping you on your journey to better health.